两种不同给药方式下表阿霉素治疗乳腺癌近期疗效观察  

Evaluation of Two Administration Way on Curative Effects of Epirubicin in Treatment of Breast Cancer

作　　者：杨润祥[1,2] 任宏轩[1,2] 聂建云[1,3] 刘林[1,2] 董超[1,2] 高春林[1,2] 庄莉[1,2] 姚萍[1,2] 

机构地区：[1]云南省肿瘤医院 [2]昆明医学院第三附属医院内二科,昆明650118 [3]昆明医学院第三附属医院乳腺病科,昆明650118

出　　处：《肿瘤防治研究》2012年第5期573-576,共4页Cancer Research on Prevention and Treatment

摘　　要：目的观察表阿霉素微量泵入与静脉滴注两种不同给药方法治疗Ⅲ、Ⅳ期乳腺癌的近期疗效,以寻找更有效的化疗给药方式。方法经病理组织学确诊的Ⅲ或Ⅳ期乳腺癌患者67例,随机分为表阿霉素微量泵入组和静脉滴注组。表阿霉素剂量为70 mg/m2,每三周重复;参照WHO标准观察和评价近期客观疗效;两周期评价疗效,两组共完成周期数214个。结果 67例均可评价客观疗效,微量泵入组:Ⅲ期患者10例,其中CR2例、PR6例、SD2例、PD0例,客观有效率(RR)80.0%(8/10),疾病控制率(DCR)100.0%(10/10);Ⅳ期患者23例中CR2例、PR13例、SD6例、PD2例,客观有效率(RR)65.2%(15/23),疾病控制率(DCR)91.3%(21/23)。静脉滴注组:Ⅲ期患者9例中CR1例、PR4例、SD3例、PD1例,客观有效率(RR)55.6%(5/9),疾病控制率(DCR)88.9%(8/9);Ⅳ期患者25例中CR0例、PR9例、SD12例、PD4例,客观有效率(RR)36.0%(9/25),疾病控制率(DCR)84.0%(21/25)。结论表阿霉素微量泵入较静脉滴注给药在治疗Ⅲ或Ⅳ期乳腺癌患者疗效上可认为具有优势(χ2=5.509,P=0.027)。因病例数少,值得临床进一步验证。Objective To evaluate the curative effects of Epirubicin（EPI） administered by means of micro-pumping and intravenous dripping in patients with breast cancer of the Ⅲ and the Ⅳ phases.Methods A total of 67 cases that were pathologically diagnosed as the Ⅲ-and Ⅳ-phase breast cancer were recruited in this study.Patients were randomly divided into two groups and received the same dosage of Epirubicin（70 mg/m2）,which was administered by micro-pumping（MP group,n=33） and intravenous dripping（ID group,n=34）,respectively.Chemotherapy repeated on a regular three-week cycle and observations of the curative effect were conducted in line with the WHO standard.Results Data from a total of 214 courses of chemotherapy were collected from the two groups of patients.All cases are assessable of their curative effects.In the MP group,10 cases of Ⅲ phase were specified as 2 cases of CR,6 PR,2 SD,but none of PD.The average remedial ratio（RR） reached 80.0%（8/10） and their disease control ratio（DCR） was 100.0%（10/10）.Of the 23 cases of the Ⅳ phase（in which 7 cases was found with liver metastasis,15 with pulmonary metastasis,and 5 with brain metastasis）,there was 2 cases of CR,13 PR,6 SD,and 2 PD.The average RR was 65.2%（15/23） and the DCR was 91.3%（21/23）.In the ID group,9 cases of Ⅲ phase were specified as 1 case of CR,4 PR,3 SD,and 1 PD.The average RR was 55.6%（5/9） and the DCR was 88.9%（8/9）.Of the 25 cases of the Ⅳ phase（in which 6 cases were found with liver metastasis,16 with pulmonary metastasis,and 4 with brain metastasis）,there were 9 cases of PR,12 SD,4 PD,but none of CR.The average RR was 36.0%（9/25） and the DCR was 84.0%（21/25）.Compared with the ID group,the curative effect of Epirubicin in the MP group turned out to be more prominent（χ2=5.509,P=0.027）.Conclusion Administration of EPI by micro-pumping had better curative effect than by using intravenous dripping.Further study with large sample size should be carried out to validate our curre

关 键 词：表阿霉素 微量泵入 静脉滴注 乳腺癌 给药方式 

分 类 号：R737.9[医药卫生—肿瘤]